Global Influenza Vaccine Market
Influenza is commonly known as “flu” or “seasonal flu” caused by influenza virus. The symptoms of influenza can be mild to severe ranging from fever to pneumonia. Influenza mainly affected by three type’s influenza virus, called type A, type B and type C. Influenza virus generally spread through the air by coughing and sneezing or touching contaminated surfaces by a virus. Influenza can be diagnosed by testing throat, sputum and nose. Numbers of rapid tests are available for detecting influenza virus. Influenza can be treated with antiviral drugs or prevented by administering influenza vaccine and several other fluid management methods. Influenza virus spreads around the world in yearly outbreaks that result in millions of severe illness and thousands of deaths across the world. WHO every year predicts few strains which are expected to circulate in following year, that allows pharmaceutical companies to develop influenza vaccine against these stains.
Recommendation by WHO and U.S’s Centers for Disease Control and Prevention (CDC) for yearly vaccination in high-risk group patients, cost of effectiveness of seasonal influenza vaccine in different age groups and settings expected to drive the market for influenza vaccine over the forecast period. Moreover reduced healthcare burden due to influenza vaccination expected to propel the market for influenza vaccine. For instance, in 2015-2016 influenza seasons, CDC estimates that influenza vaccination prevented approximately 5.1 million influenza illnesses, 2.5 million influenza-associated medical visits, and 71,000 influenza-associated hospitalizations. However, Influenza vaccine made in a year may not be effective in following year owing to evolving nature of influenza virus, in healthy individual influenza vaccine is modestly effective, sometimes new strain or overlooked strain become prevalent in that season, and product recalls which may hamper the uptake and growth.
Influenza Vaccines market has been segmented on the basis of vaccine type, strain type, formulation type, end user, and region
Based on vaccine type:
- Killed or Inactivated Vaccine
- Live Vaccine
Based on strain type:
- Trivalent Influenza Vaccine
- Quadrivaleant Influenza Vaccine
Based on formulation type:
- Nasal Sprays
Based on distribution channel:
- Government Immunization programmes
- Non Governmental Organizations (NGOs)
Players in influenza vaccines market focusing on developing effective vaccine i.e.quadrivalent against influenza virus and eyeing on expanding geographic presence to increase the market revenue for influenza vaccine products. For Instance, in June 2016, Sanofi received a positive end of a procedure from the German which helps in getting market authorization for VaxigripTetra, a quadrivalent vaccine against influenza. Several leading players in influenza vaccine market shipping the vaccine to U.S. market to meet seasonal demand in the country. Securing government tenders has become essential for influenza vaccine manufacturers to gain larger market share and helps in sustaining the business. For instance, in 2015, Sinovac Biotech Ltd. received the tender award from Beijing government to supply seasonal influenza vaccine.
Influenza Vaccines market has been segmented into five regions Viz. North Americas, Europe, Asia Pacific, Latin America and the Middle East and Africa. Each year, there are two seasons of influenza because of northern and southern hemispheres have winter in different times. An occurrence of influenza infections high in developing countries than developed counters which make the market lucrative for players in developing countries. However in North America expected to witness significant growth owing U.S.’s yearly vaccination programme. In Europe influenza vaccine limited to the high-risk groups rather than blanket vaccination programmes which market to grow at moderate growth rate. Asia Pacific market expected to grow at significant CAGR owing to increasing affordability, larger and subsidized immunization programs in several countries in the Asia region.
Some of the players in the market include GlaxoSmithKline plc., Seqirus (CSL Limited), AstraZeneca, Sanofi Pasteur Inc., Sinovac Biotech Ltd., Novavax, Inc., DAIICHI SANKYO COMPANY, LIMITED., Mitsubishi Tanabe Pharma., Protein Sciences Corporation to name a few. There are several influenza vaccine candidates in a late-stage clinical pipeline which are expected hit the market in the forecast period. For instance, in 2017 Daiichi Sankyo’s VN-100 and MEDI3250 influenza vaccine expected to get market approval in Japan.
- In Jan 2016, CSL Limited acquired Novartis AG’s influenza vaccine business in Germany, as a part of global influenza vaccine
- In June 2016, Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has recommended not to use AstraZeneca’s FluMist Quadrivalent Influenza vaccine in any settings owing to lack of statistically significant effectiveness in children
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2024
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario